Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 3/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18038541 | 0.87 | PIK3CD (0.51) | PIK3CDKCNH2PDE4APDE4BPDE4C | |
| SCHEMBL14742248 | 0.87 | PIK3CD (0.51) | PIK3CDKCNH2PDE4APDE4BPDE4C | |
| SCHEMBL14742491 | 0.85 | PIK3CD (0.51) | PIK3CDKCNH2PDE4APDE4BPDE4C | |
| SCHEMBL17337252 | 0.84 | PIK3CD (0.52) | PIK3CDKCNH2PDE4A | |
| SCHEMBL18038542 | 0.84 | PIK3CD (0.47) | PIK3CDKCNH2PDE4APDE4BPDE4C | |
| SCHEMBL18038537 | 0.80 | PIK3CD (0.47) | PIK3CDKCNH2PDE4APDE4BPDE4C | |
| SCHEMBL18042426 | 0.80 | PIK3CD (0.55) | PIK3CDKCNH2PDE4A | |
| SCHEMBL18042424 | 0.80 | PIK3CD (0.55) | PIK3CDKCNH2PDE4A | |
| SCHEMBL17337229 | 0.80 | PIK3CD (0.47) | PIK3CDKCNH2PDE4A | |
| SCHEMBL18038547 | 0.78 | PIK3CD (0.43) | PIK3CDKCNH2PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336759-B2 | Salts and processes of preparing a PI3K inhibitor | INCYTE CORPORATION (US) | 2019-07-02 | — | — | US | disclosed |
| US-20160257689-A1 | SALTS AND PROCESSES OF PREPARING A PI3K INHIBITOR | INCYTE CORPORATION | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336759-B2 | Salts and processes of preparing a PI3K inhibitor | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885KCNH2 941/4885PDE4A 1129/4885 |
| US-20160257689-A1 | SALTS AND PROCESSES OF PREPARING A PI3K INHIBITOR | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885KCNH2 941/4885PDE4A 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.